QQQ   298.44 (-1.16%)
AAPL   145.54 (-1.07%)
MSFT   261.50 (+0.15%)
FB   200.04 (+0.71%)
GOOGL   2,288.90 (-1.38%)
AMZN   2,216.21 (-1.99%)
TSLA   724.37 (-5.88%)
NVDA   172.64 (-2.50%)
BABA   86.48 (-1.72%)
NIO   14.55 (+1.68%)
AMD   94.24 (-0.93%)
CGC   5.73 (-3.21%)
MU   70.47 (-2.02%)
T   20.28 (+2.22%)
GE   74.63 (-0.56%)
F   13.05 (-3.33%)
DIS   105.18 (-2.00%)
AMC   11.71 (-0.85%)
PFE   50.67 (+1.50%)
PYPL   77.65 (-1.50%)
NFLX   186.51 (-0.60%)
QQQ   298.44 (-1.16%)
AAPL   145.54 (-1.07%)
MSFT   261.50 (+0.15%)
FB   200.04 (+0.71%)
GOOGL   2,288.90 (-1.38%)
AMZN   2,216.21 (-1.99%)
TSLA   724.37 (-5.88%)
NVDA   172.64 (-2.50%)
BABA   86.48 (-1.72%)
NIO   14.55 (+1.68%)
AMD   94.24 (-0.93%)
CGC   5.73 (-3.21%)
MU   70.47 (-2.02%)
T   20.28 (+2.22%)
GE   74.63 (-0.56%)
F   13.05 (-3.33%)
DIS   105.18 (-2.00%)
AMC   11.71 (-0.85%)
PFE   50.67 (+1.50%)
PYPL   77.65 (-1.50%)
NFLX   186.51 (-0.60%)
QQQ   298.44 (-1.16%)
AAPL   145.54 (-1.07%)
MSFT   261.50 (+0.15%)
FB   200.04 (+0.71%)
GOOGL   2,288.90 (-1.38%)
AMZN   2,216.21 (-1.99%)
TSLA   724.37 (-5.88%)
NVDA   172.64 (-2.50%)
BABA   86.48 (-1.72%)
NIO   14.55 (+1.68%)
AMD   94.24 (-0.93%)
CGC   5.73 (-3.21%)
MU   70.47 (-2.02%)
T   20.28 (+2.22%)
GE   74.63 (-0.56%)
F   13.05 (-3.33%)
DIS   105.18 (-2.00%)
AMC   11.71 (-0.85%)
PFE   50.67 (+1.50%)
PYPL   77.65 (-1.50%)
NFLX   186.51 (-0.60%)
QQQ   298.44 (-1.16%)
AAPL   145.54 (-1.07%)
MSFT   261.50 (+0.15%)
FB   200.04 (+0.71%)
GOOGL   2,288.90 (-1.38%)
AMZN   2,216.21 (-1.99%)
TSLA   724.37 (-5.88%)
NVDA   172.64 (-2.50%)
BABA   86.48 (-1.72%)
NIO   14.55 (+1.68%)
AMD   94.24 (-0.93%)
CGC   5.73 (-3.21%)
MU   70.47 (-2.02%)
T   20.28 (+2.22%)
GE   74.63 (-0.56%)
F   13.05 (-3.33%)
DIS   105.18 (-2.00%)
AMC   11.71 (-0.85%)
PFE   50.67 (+1.50%)
PYPL   77.65 (-1.50%)
NFLX   186.51 (-0.60%)
NASDAQ:XOMA

XOMA (XOMA) Stock Forecast, Price & News

$17.26
+0.05 (+0.29%)
(As of 05/16/2022 12:00 AM ET)
Add
Compare
Today's Range
$17.05
$17.59
50-Day Range
$17.05
$29.61
52-Week Range
$16.96
$39.02
Volume
43,685 shs
Average Volume
30,483 shs
Market Capitalization
$197.13 million
P/E Ratio
32.57
Dividend Yield
N/A
Beta
1.09
30 days | 90 days | 365 days | Advanced Chart
Receive XOMA News and Ratings via Email

Sign-up to receive the latest news and ratings for XOMA and its competitors with MarketBeat's FREE daily newsletter.

XOMA logo

About XOMA

XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

Headlines

XOMA (NASDAQ:XOMA) Given "Buy" Rating at HC Wainwright
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:XOMA
CUSIP
98419J10
Employees
12
Year Founded
1981

Sales & Book Value

Annual Sales
$38.16 million
Cash Flow
$0.72 per share
Book Value
$12.25 per share

Profitability

Net Income
$15.80 million
Pretax Margin
51.31%

Debt

Price-To-Earnings

Miscellaneous

Free Float
10,176,000
Market Cap
$197.13 million
Optionable
Not Optionable

Company Calendar

Last Earnings
5/05/2022
Today
5/16/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

Social Links


MarketRank

Overall MarketRank

2.17 out of 5 stars

Medical Sector

394th out of 1,423 stocks

Pharmaceutical Preparations Industry

158th out of 678 stocks

Analyst Opinion: 3.3Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -













XOMA (NASDAQ:XOMA) Frequently Asked Questions

Is XOMA a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for XOMA in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" XOMA stock.
View analyst ratings for XOMA
or view top-rated stocks.

When is XOMA's next earnings date?

XOMA is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for XOMA
.

How were XOMA's earnings last quarter?

XOMA Co. (NASDAQ:XOMA) announced its quarterly earnings data on Thursday, May, 5th. The biotechnology company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.02. The biotechnology company had revenue of $3.11 million for the quarter, compared to analyst estimates of $3.56 million. XOMA had a net margin of 27.35% and a trailing twelve-month return on equity of 8.77%.
View XOMA's earnings history
.

What price target have analysts set for XOMA?

3 brokerages have issued 1 year target prices for XOMA's shares. Their forecasts range from $22.00 to $69.00. On average, they anticipate XOMA's stock price to reach $49.00 in the next twelve months. This suggests a possible upside of 183.9% from the stock's current price.
View analysts' price targets for XOMA
or view top-rated stocks among Wall Street analysts.

Who are XOMA's key executives?
XOMA's management team includes the following people:
What is John Varian's approval rating as XOMA's CEO?

11 employees have rated XOMA CEO John Varian on Glassdoor.com. John Varian has an approval rating of 73% among XOMA's employees.

What other stocks do shareholders of XOMA own?
What is XOMA's stock symbol?

XOMA trades on the NASDAQ under the ticker symbol "XOMA."

Who are XOMA's major shareholders?

XOMA's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (4.04%), Vanguard Group Inc. (3.55%), State Street Corp (1.15%), Northern Trust Corp (0.75%), Strs Ohio (0.22%) and Dimensional Fund Advisors LP (0.07%). Company insiders that own XOMA stock include Bvf Partners L P/Il, James R Neal, James R Neal, Matthew D Perry, Thomas M Burns and Value Fund L P Biotechnology.
View institutional ownership trends for XOMA
.

Which major investors are selling XOMA stock?

XOMA stock was sold by a variety of institutional investors in the last quarter, including Strs Ohio, Northern Trust Corp, Vanguard Group Inc., and BlackRock Inc.. Company insiders that have sold XOMA company stock in the last year include James R Neal, and Thomas M Burns.
View insider buying and selling activity for XOMA
or view top insider-selling stocks.

Which major investors are buying XOMA stock?

XOMA stock was acquired by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Citigroup Inc., State Street Corp, and UBS Group AG. Company insiders that have bought XOMA stock in the last two years include Bvf Partners L P/Il, Matthew D Perry, and Value Fund L P Biotechnology.
View insider buying and selling activity for XOMA
or or view top insider-buying stocks.

How do I buy shares of XOMA?

Shares of XOMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is XOMA's stock price today?

One share of XOMA stock can currently be purchased for approximately $17.26.

How much money does XOMA make?

XOMA has a market capitalization of $197.13 million and generates $38.16 million in revenue each year. The biotechnology company earns $15.80 million in net income (profit) each year or $0.529990 on an earnings per share basis.

How many employees does XOMA have?

XOMA employs 12 workers across the globe.

When was XOMA founded?

XOMA was founded in 1981.

What is XOMA's official website?

The official website for XOMA is www.xoma.com.

How can I contact XOMA?

XOMA's mailing address is 2200 POWELL STREET SUITE 310, EMERYVILLE CA, 94608. The biotechnology company can be reached via phone at (510) 204-7200, via email at [email protected], or via fax at 510-649-7571.

This page was last updated on 5/16/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.